-
The Health Commission urgently notified and strictly investigated unreasonable out-of-hospital prescriptions!
Time of Update: 2021-09-20
According to Dami’s understanding, the Chongqing Municipal Health Commission has issued the "Emergency Notice on Further Strengthening the Management of Clinical Rational Drug Use in Medical Institutions".
-
Top 20 most influential pharmaceutical R&D executives in the world
Time of Update: 2021-09-20
John Leonard: the pioneer of gene editing LNP technologyJohn LeonardJohn Leonard was the senior vice president of global drug development at AbbVie and currently serves as the chief executive officer (CEO) of Intellia Therapeutics .
-
Sinopharm Hyundai Ceftriaxone Sodium for Injection Obtained Marketing License in Malta
Time of Update: 2021-09-20
On September 3, Sinopharm Hyundai issued an announcement stating that DALI PharmaGmbH, a wholly-owned subsidiary established by its holding subsidiary Zhijun Pharmaceuticals in Germany, received the approval of the Malta Pharmaceutical Regulatory Authority to issue ceftriaxone sodium for injection (250mg/500mg/ 1g) Marketing authorization .
Its indication is that ceftriaxone sodium is a long-acting, broad-spectrum third-generation cephalosporin antibiotic.
-
Buchang Pharmaceutical's wholly-owned subsidiary obtained the notice of supplementary application for Tiangui menopause soft capsule drugs
Time of Update: 2021-09-20
("Shaanxi Buchang"), had recently received the "Tiangui Gengnian Soft Capsule" approved and issued by the State Drug Administration.
Tiangui Gengnian Soft Capsule has the functions of nourishing liver and kidney, promoting blood circulation and removing blood stasis .
-
Tianyao Amino Acid (15) Peritoneal Dialysis Solution Obtained Drug Registration Certificate
Time of Update: 2021-09-20
On August 27, Tianyao issued an announcement stating that its subsidiary Jinyao Pharmaceutical had recently received the "Drug Registration Certificate" for amino acid (15) peritoneal dialysate approved and issued by the State Food and Drug Administration .
-
Simcere Pharmaceuticals Announcement of Mid-2021 Results: Increased R&D Investment and Accelerated Innovation and Transformation
Time of Update: 2021-09-20
Simcere’s interim results report shows that: the central nervous system disease drug portfolio (main products must be new and must be stored) revenue reached 595 million yuan, accounting for 28.
-
Notice: The township health center is the main body to carry out rounds of consultations and stationed services
Time of Update: 2021-09-20
Visits: Qualified physicians in township hospitals should be selected, and if necessary, a round-trip team consisting of physicians, nurses, public health personnel, and auxiliary department personnel may be formed to carry out services .
-
Internet medical treatment actually gives drug rebates?
Time of Update: 2021-09-20
Good Doctor Online said that recently, Good Doctor received feedback from doctors online, claiming that an emerging Internet medical platform sent information to the doctor, inviting doctors to open the online platform, saying "The policy is: original research (drug) 5%-10%, domestically produced (Medicine) 10%-20% (commission), settled in the form of consulting fees, and does not calculate personal income tax .
-
Three new anti-tumor drugs are planned to be included in breakthrough treatment varieties
Time of Update: 2021-09-20
Text|Pharmaceutical Mission HillsAccording to the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China, three new anti-tumor drugs are planned to be included in breakthrough treatment products, which come from Haihe Pharmaceutical, Hutchison Medicine, and Five Prime Therapeutics under Amgen .
-
Bayer/Zhiben larotrectinib companion diagnostic reagent passed special review for innovative medical devices
Time of Update: 2021-09-20
On August 22, Zhiben Medical announced that the human NTRK1/2/3 gene mutation detection kit (reversible terminal termination sequencing method) has been awarded the "Special Review of Innovative Medical Devices" by the Medical Device Technology Evaluation Center of the State Drug Administration .
-
Hebei Provincial Food and Drug Administration Publicly Solicits Opinions on the Implementation Rules for the Management of Chinese Medicine Formula Granules
Time of Update: 2021-09-20
Chapter 2 Production Management Article 5 A Chinese medicine manufacturer that produces Chinese medicine formula granules shall meet the following conditions: (1) Established in accordance with the law in China and able to independently assume responsibility (including the ability to assume responsibility for drug quality and safety) .
-
Target PD-1 and LAG-3!
Time of Update: 2021-09-20
Text|Pharmaceutical Mission HillsThe Center for Drug Evaluation (CDE) of the National Medical Products Administration of China revealed that Roche's application for a new class 1 drug RO7247669 injection has obtained an implied license for a clinical trial and is intended to be developed for the treatment of liver cancer .
-
Heqirui Medicine Appoints Dr. Henri Doods as Chief Executive Officer
Time of Update: 2021-09-20
(and Qirui Medicine) announced the appointment of the former president and head of clinical research and development Dr.
Henri Nico Doods served as the senior vice president of Boehringer Ingelheim and the global head of Boehringer Ingelheim Research Beyond Border-RBB before joining Heqirui Medicine.
-
JAK inhibitor approved for the first time for the treatment of eczema, upatinib received EU approval for the fourth indication
Time of Update: 2021-09-20
On August 24, 2021, AbbVie announced that the European Commission (EC) approved its oral JAK inhibitor upadacitinib (upadacitinib, English trade name Rinvoq) to expand its indications for the treatment of suitable systemic For adults and adolescents over 12 years of age with moderate/severe atopic dermatitis, they can choose whether to use it in combination with topical corticosteroids (TCS) .
-
The raw material drug Cetirizine Hydrochloride, a wholly-owned subsidiary of Warner Pharmaceuticals, passed the CDE approval
Time of Update: 2021-09-20
passed the CDE approval .
Cetirizine hydrochloride, the second-generation histamine H1 receptor antagonist (anti-allergic drug), is mainly used for respiratory, skin and eye allergic diseases, including perennial allergic diseases, such as allergic skin diseases, Look for measles, allergic rhinitis, itchy eyes, conjunctivitis and asthma .
-
Ningxia Hui Autonomous Region Food and Drug Administration Publicly Solicits Opinions on Management Rules of Chinese Medicine Formula Granules
Time of Update: 2021-09-20
On September 7, the Drug Administration of Ningxia Hui Autonomous Region issued a notice on the public solicitation of "Rules for the Management of Traditional Chinese Medicine Formula Granules in Nin
-
Kelun Pharmaceutical's net profit increased by 142.96% in the first half of the year, 12 innovative drug pipeline progress disclosures
Time of Update: 2021-09-20
On August 25, Kelun Pharmaceutical released a semi-annual report . In the first half of the year, revenue was 8. 232 billion yuan, a year-on-year increase of 13. 84%; net profit was 493 million yuan
-
Jingxin Pharmaceutical signed an agreement with South Korea's B-PS Company to introduce JBPOS0101
Time of Update: 2021-09-20
According to the agreement, the company has obtained two clinical indications (infant spasm is in phase II clinical trials in the United States, and focal epilepsy has completed phase I clinical trials in the United States) in mainland China (including Hong Kong, Macau) exclusive clinical research and development, production and commercialization rights .
-
Nature: Prospects for the mRNA drug market in 2035
Time of Update: 2021-09-20
Taking into account the target population penetration rate, pricing and competition for the main indications, it is estimated that the average global peak sales of preventive mRNA vaccine drugs (products other than the COVID-19 vaccine) are about 800 million US dollars .
-
Chen Jianming, deputy general manager of Pien Tze Huang, resigns after retirement
Time of Update: 2021-09-20
Chen Jianming reached the legal retirement age, he applied to the board of directors for retirement and resigned from the position of deputy general manager of the company .
Chen Jianming's resignation report will take effect from the day it is delivered to the company's board of directors .
